Lupin Ltd. is Rated Buy by MarketsMOJO

Current Rating Overview

On 16 February 2026, Lupin Ltd.'s rating was revised from 'Strong Buy' to 'Buy' by MarketsMOJO, with the Mojo Score adjusting from 81 to 78. This rating reflects a solid investment case, signalling that the stock remains attractive for investors seeking growth potential within the Pharmaceuticals & Biotechnology sector. The 'Buy' rating indicates confidence in Lupin’s quality and financial health, while also recognising a more measured valuation and technical stance compared to the previous assessment.

How Lupin Ltd. Looks Today: Quality Assessment

As of 23 March 2026, Lupin Ltd. maintains a strong quality grade, reflecting its robust operational performance and prudent financial management. The company’s low average debt-to-equity ratio of 0.10 times underscores a conservative capital structure, reducing financial risk and enhancing stability. This low leverage is particularly favourable in the pharmaceutical sector, where steady investment in research and development is crucial.

Moreover, Lupin has demonstrated healthy long-term growth, with net sales increasing at an annualised rate of 11.42% and operating profit expanding by 33.60%. These figures highlight the company’s ability to grow revenue while improving operational efficiency, a key marker of quality for investors seeking sustainable earnings growth.

Valuation: Attractive Yet Balanced

The valuation grade for Lupin Ltd. is currently rated as attractive. The stock trades at a price-to-book value of 5.4, which, while elevated, is considered reasonable given the company’s strong return on equity (ROE) of 22%. This ROE level indicates effective utilisation of shareholder capital to generate profits.

Importantly, Lupin’s valuation is discounted relative to its peers’ historical averages, offering investors a favourable entry point. The company’s price-to-earnings-to-growth (PEG) ratio stands at a low 0.3, signalling that the stock’s price growth potential is undervalued relative to its earnings growth rate. Over the past year, Lupin has delivered an 8.55% return to shareholders, while profits surged by 73.5%, reinforcing the stock’s compelling valuation narrative.

Financial Trend: Positive Momentum

The financial trend for Lupin Ltd. remains positive, supported by consistent quarterly performance and strong profitability metrics. The company has reported positive results for the last three consecutive quarters, with key indicators such as return on capital employed (ROCE) reaching a high of 22.22% in the half-year period. This level of capital efficiency is a strong signal of Lupin’s operational effectiveness.

Additionally, profit before tax excluding other income (PBT less OI) for the most recent quarter stood at ₹1,833.91 crores, reflecting a robust growth rate of 43.6% compared to the previous four-quarter average. Net sales for the quarter also hit a record high of ₹7,167.52 crores, underscoring the company’s expanding market presence and demand for its products.

Technicals: Bullish Outlook

From a technical perspective, Lupin Ltd. exhibits a bullish trend. The stock has shown resilience and steady appreciation, with returns of +2.00% over the past month, +8.36% over three months, and +14.17% over six months. Year-to-date, the stock has gained 8.43%, and over the last year, it has delivered an 8.19% return. These figures indicate sustained investor interest and positive momentum in the share price.

Institutional investors hold a significant 47.08% stake in Lupin, reflecting confidence from knowledgeable market participants who typically conduct thorough fundamental analysis. This high institutional holding often provides stability and can be a positive signal for retail investors.

What the 'Buy' Rating Means for Investors

The 'Buy' rating assigned to Lupin Ltd. by MarketsMOJO suggests that the stock is expected to outperform the broader market over the medium term. This recommendation is grounded in the company’s strong fundamentals, attractive valuation, positive financial trends, and supportive technical indicators. Investors can interpret this rating as a signal that Lupin offers a favourable risk-reward profile, combining growth potential with financial stability.

However, the rating also reflects a cautious stance compared to the previous 'Strong Buy' grade, indicating that while Lupin remains a compelling investment, certain valuation or market factors warrant a more measured approach. This balanced view encourages investors to consider Lupin as a core portfolio holding, particularly for those focused on the Pharmaceuticals & Biotechnology sector, but to remain attentive to market developments and company performance updates.

Sector and Market Context

Lupin operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory complexity, and steady demand. The company’s midcap status positions it well to benefit from both domestic growth opportunities and international expansion. Its consistent financial performance and low leverage provide a competitive advantage in navigating sector challenges.

Compared to the broader market, Lupin’s recent returns and profit growth outpace many peers, reinforcing its standing as a quality midcap stock. The company’s ability to sustain growth while maintaining attractive valuation metrics is a key factor supporting the current 'Buy' rating.

Investor Takeaway

For investors considering Lupin Ltd., the current 'Buy' rating offers a clear endorsement of the company’s prospects as of 23 March 2026. The stock’s strong quality indicators, attractive valuation, positive financial momentum, and bullish technical signals combine to present a compelling investment case. While the rating is slightly more conservative than before, it still reflects confidence in Lupin’s ability to deliver shareholder value over time.

Investors should continue to monitor quarterly results, sector developments, and broader market conditions to ensure alignment with their investment objectives. Lupin’s demonstrated resilience and growth trajectory make it a noteworthy candidate for portfolios seeking exposure to the pharmaceutical sector’s growth potential.

Summary

In summary, Lupin Ltd. is rated 'Buy' by MarketsMOJO as of the latest update on 16 February 2026. The analysis presented here, based on data current to 23 March 2026, highlights the company’s strong fundamentals, attractive valuation, positive financial trends, and bullish technical outlook. This rating signals a favourable investment opportunity for those seeking growth in the Pharmaceuticals & Biotechnology sector, supported by solid operational performance and prudent financial management.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today